PYC Stock Overview
A drug-development company, engages in the discovery and development of drug solutions in the areas of RNA therapeutics in Australia.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
PYC Therapeutics Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.10 |
52 Week High | AU$0.12 |
52 Week Low | AU$0.052 |
Beta | 0.60 |
1 Month Change | 16.67% |
3 Month Change | 34.62% |
1 Year Change | 84.21% |
3 Year Change | -27.59% |
5 Year Change | 337.50% |
Change since IPO | -59.62% |
Recent News & Updates
Recent updates
Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth
Apr 10Is PYC Therapeutics (ASX:PYC) In A Good Position To Deliver On Growth Plans?
Nov 10We Think PYC Therapeutics (ASX:PYC) Needs To Drive Business Growth Carefully
Jul 03Here's Why We're Watching PYC Therapeutics' (ASX:PYC) Cash Burn Situation
Jan 25Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth
Jul 31We're Not Very Worried About PYC Therapeutics' (ASX:PYC) Cash Burn Rate
Mar 28Non-Executive Chair of the Board Alan Tribe Just Bought A Handful Of Shares In PYC Therapeutics Limited (ASX:PYC)
Feb 20Have Insiders Been Selling PYC Therapeutics Limited (ASX:PYC) Shares?
Jan 26What You Need To Know About PYC Therapeutics Limited's (ASX:PYC) Investor Composition
Dec 22We Think PYC Therapeutics (ASX:PYC) Can Easily Afford To Drive Business Growth
Nov 17Shareholder Returns
PYC | AU Biotechs | AU Market | |
---|---|---|---|
7D | 0% | -0.5% | 1.5% |
1Y | 84.2% | -9.2% | 8.7% |
Return vs Industry: PYC exceeded the Australian Biotechs industry which returned -9.2% over the past year.
Return vs Market: PYC exceeded the Australian Market which returned 8.7% over the past year.
Price Volatility
PYC volatility | |
---|---|
PYC Average Weekly Movement | 10.1% |
Biotechs Industry Average Movement | 11.4% |
Market Average Movement | 9.0% |
10% most volatile stocks in AU Market | 17.7% |
10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: PYC's share price has been volatile over the past 3 months.
Volatility Over Time: PYC's weekly volatility (10%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | n/a | Rohan Hockings | pyctx.com |
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of RNA therapeutics in Australia. The company’s preclinical development programs include VP-001, a drug program for retinitis pigmentosa type 11; PYC-001, a drug program for the treatment of autosomal dominant optic atrophy; and PYC-002 a drug program for the treatment of a severe neurodevelopmental disorder. It also focuses on the development of programs for kidney, neurodevelopmental, retinal, and central nervous system diseases.
PYC Therapeutics Limited Fundamentals Summary
PYC fundamental statistics | |
---|---|
Market cap | AU$489.94m |
Earnings (TTM) | -AU$21.65m |
Revenue (TTM) | AU$21.24m |
23.1x
P/S Ratio-22.6x
P/E RatioIs PYC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PYC income statement (TTM) | |
---|---|
Revenue | AU$21.24m |
Cost of Revenue | AU$0 |
Gross Profit | AU$21.24m |
Other Expenses | AU$42.89m |
Earnings | -AU$21.65m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.0046 |
Gross Margin | 100.00% |
Net Profit Margin | -101.90% |
Debt/Equity Ratio | 0% |
How did PYC perform over the long term?
See historical performance and comparison